"Emerging technologies such as regenerative medicine will only increase the complexity of the logistics systems that need to be validated, especially as the requirements of the Drug Supply Chain Security act come into force," Mark W. Sawicki, Ph.D., Chief Commercial officer of Cryoport, discusses validation standards and pharmaceutical logistics as biotechnology advances in a recent article in Pharmaceutical Outsourcing. Read more >
